It's time for an update on the Medical company Grifols, S.A. (NASDAQ:GRFS). It's been about 4 months since I last updated on the business, with that update being specific to an event where ...

Grifols announced on Thursday that it has signed a strategic agreement with Swiss laboratory automation firm Inpeco to provide automated instrumentation, robotics, and software to transfusion medicine ...

GRIFOLS transfer bags are used for sterile preservation and administration of blood components. Blood components can be obtained, stored and preserved without contact with the environment ensuring ...

Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J. Fox Foundation for Parkinson’s ...

Grifols SA engages in the production of plasma ... The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked ...

Immunoglobulin therapy improves mobility in phase 2/3 study Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous immunoglobulin ...

Grifols, S.A. (NASDAQ:GRFS) delivered strong financial results in Q3 2024, showing solid growth and improved financial health. Revenue reached EUR 1,793 million, reflecting a 12.4% year-over-year ...

Grifols is anticipating a period of strong growth ... As the news that NHS England is to be dismantled sinks in, the British Medical Association (BMA) and other bodies have weighed in on the ...

Grifols (GRFS) issued a statement to address certain information published in a media outlet on March 8, specifically a front-page article titled “The CNMV reveals to the judge ‘continuous ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Spanish pharmaceutical firm Grifols saw its shares surge by 11% on Thursday, following a significant rise in its third-quarter net ...